{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:25:50Z","timestamp":1790558750601,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"National Institutes of Health Fogarty International Center","doi-asserted-by":"publisher","award":["K43 TW012350"],"award-info":[{"award-number":["K43 TW012350"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["PSIA2020-3073"],"award-info":[{"award-number":["PSIA2020-3073"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2018SF-2458"],"award-info":[{"award-number":["TMA2018SF-2458"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["PSIA2020AGDG-3319"],"award-info":[{"award-number":["PSIA2020AGDG-3319"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jgar.2025.12.005","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:28:25Z","timestamp":1765556905000},"page":"171-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-8746","authenticated-orcid":false,"given":"Tuelo","family":"Mogashoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justice T.","family":"Ngom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Loubser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedumetse","family":"Seru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuduetso","family":"Molefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"One","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary M.","family":"Musonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simani","family":"Gaseitsiwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzaan","family":"Dippenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Streicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.12.005_bib0001","unstructured":"WHO. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB\/RIF system 2011 [accessed 18.08.2025]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/44586\/9789241501545_eng.pdf?sequence=1."},{"issue":"12","key":"10.1016\/j.jgar.2025.12.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261084","article-title":"Diagnostic accuracy of truenat tuberculosis and rifampicin-resistance assays in Addis Ababa, Ethiopia","volume":"16","author":"Meaza","year":"2021","journal-title":"PLoS One."},{"issue":"8","key":"10.1016\/j.jgar.2025.12.005_bib0003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jmoldx.2024.05.004","article-title":"Accuracy of cobas MTB and MTB-RIF\/INH for Detection of Mycobacterium tuberculosis and drug resistance","volume":"26","author":"de Vos","year":"2024","journal-title":"J Mol Diagnost"},{"issue":"5","key":"10.1016\/j.jgar.2025.12.005_bib0004","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cid\/ciz932","article-title":"Multicenter study of the accuracy of the BD MAX multidrug-resistant tuberculosis assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid","volume":"71","author":"Shah","year":"2020","journal-title":"Clin Infectious Dis"},{"key":"10.1016\/j.jgar.2025.12.005_bib0005","year":"2024"},{"issue":"9","key":"10.1016\/j.jgar.2025.12.005_bib0006","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1128\/JCM.01377-13","article-title":"Diagnostic implications of inconsistent results obtained with the Xpert MTB\/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance","volume":"51","author":"Somoskovi","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.jgar.2025.12.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01885-20","article-title":"Low-level rifampin resistance and rpob mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York","volume":"59","author":"Shea","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2025.12.005_bib0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jgar.2024.12.026","article-title":"Detection of I491F and V170F rpoB mutations associated with misdiagnosis of rifampicin resistance among patients with drug-susceptible tuberculosis treatment failure, Myanmar, 2022","volume":"41","author":"Ei","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.12.005_bib0009","doi-asserted-by":"crossref","first-page":"e5895","DOI":"10.7717\/peerj.5895","article-title":"MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates","volume":"6","author":"Kohl","year":"2018","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.jgar.2025.12.005_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13073-019-0650-x","article-title":"Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs","volume":"11","author":"Phelan","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.jgar.2025.12.005_bib0011","series-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance","year":"2023"},{"issue":"11","key":"10.1016\/j.jgar.2025.12.005_bib0012","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.3201\/eid2911.230987","article-title":"Tuberculosis variant with Rifampin resistance undetectable by Xpert MTB\/RIF, Botswana","volume":"29","author":"Modongo","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2025.12.005_bib0013","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13073-020-00793-8","article-title":"MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era","volume":"12","author":"Beckert","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.jgar.2025.12.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8253546","article-title":"Mutations in Mycobacterium tuberculosis isolates with discordant results for drug-susceptibility testing in Peru","volume":"2020","author":"Solari","year":"2020","journal-title":"Int J Microbiol"},{"issue":"1","key":"10.1016\/j.jgar.2025.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.4102\/ajlm.v12i1.1975","article-title":"Consequences of rpoB mutations missed by the GenoType MTBDRplus assay in a programmatic setting in South Africa","volume":"12","author":"Mvelase","year":"2023","journal-title":"Afr J Lab Med"},{"issue":"3","key":"10.1016\/j.jgar.2025.12.005_bib0016","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1473-3099(23)00498-X","article-title":"Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB\/RIF in Mozambique: a retrospective observational study","volume":"24","author":"Barilar","year":"2024","journal-title":"Lancet Infectious Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:47:41Z","timestamp":1781509661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"alternative-id":["S2213716525002735"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.12.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}